Renal lipotoxicity in diabetic and obesity‐associated kidney diseases: Molecular mechanisms and therapeutic targeting
Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 60-82
DOI: 10.1111/dom.70220 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.10.2025. Verfasst von Qing Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Shandong Second Medical University, Weifang, China. Hauptthemen laut MEDLINE: Obesity, Diabetic Nephropathies, Kidney, Kidney Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 226 Literaturangaben. Gefördert von: The Program of Scientific and Technological Development of Weifang, The Program of Medical Science and Technology Development of Weifang, The Tai-Shan Scholar Program from Shandong Province.
Abstract (Originalsprache)
Metabolic disorders, including diabetes mellitus and obesity, have become major global health burdens that significantly increase the risk of kidney disease. A central pathological feature linking these conditions is lipotoxicity—the deleterious effects of lipid overload on cellular and organ function. In the kidney, lipotoxicity contributes to disease pathogenesis through a complex interplay of molecular mechanisms—such as mitochondrial dysfunction, impaired autophagy, oxidative stress, endoplasmic reticulum stress, and sustained inflammatory responses—which are detailed with a focus on their cell‐specific effects in podocytes and proximal tubular cells. These pathological processes collectively disrupt renal cellular homeostasis, promote cell death, and drive progressive fibrosis, ultimately leading to functional decline. Despite significant advances in our understanding of metabolic kidney diseases, effective pharmacological interventions specifically addressing renal lipotoxicity remain strikingly limited. Current therapeutic strategies should extend beyond mere lipid reduction to comprehensively address the underlying metabolic dysregulation and its downstream cellular consequences. This review aims to analyse the pathogenic molecular mechanisms and potential therapeutic agents for renal lipotoxicity in diabetic and obesity‐associated kidney diseases. It systematically examines the cell‐type‐specific injury mechanisms, lipotoxicity‐induced renal injury, and the available evidence from both preclinical studies and clinical trials of metabolically active agents with renoprotective effects, with a view to offering novel insights and informing future therapeutic strategies for metabolic kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Shandong Second Medical University, Weifang, China.
ORCID-Profile: Xiangyu Zou
Förderung
- The Program of Scientific and Technological Development of Weifang
- The Program of Medical Science and Technology Development of Weifang
- The Tai-Shan Scholar Program from Shandong Province
Zitieren
APA
Liu, Q., Guo, S., Tong, Y., Qiu, L., Zhuang, B., Wang, J., Wang, Y., Gao, W., & Zou, X. (2026). Renal lipotoxicity in diabetic and obesity‐associated kidney diseases: Molecular mechanisms and therapeutic targeting. Diabetes, Obesity and Metabolism, 28(1), 60-82. https://doi.org/10.1111/dom.70220
Vancouver
Liu Q, Guo S, Tong Y, Qiu L, Zhuang B, Wang J, et al. Renal lipotoxicity in diabetic and obesity‐associated kidney diseases: Molecular mechanisms and therapeutic targeting. Diabetes, Obesity and Metabolism. 2026;28(1):60-82. doi:10.1111/dom.70220
BibTeX
@article{Liu2026,
author = {Liu, Qing and Guo, Shangze and Tong, Yinghao and Qiu, Li and Zhuang, Baoxiang and Wang, Jingyi and Wang, Yiru and Gao, Wei and Zou, Xiangyu},
title = {Renal lipotoxicity in diabetic and obesity‐associated kidney diseases: Molecular mechanisms and therapeutic targeting},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {1},
pages = {60--82},
doi = {10.1111/dom.70220}
}
EUVIMED